Home › Funds › GREAT POINT PARTNERS LLC › NGNE
GREAT POINT PARTNERS LLC position in NGNE
NEUROGENE INC COM · Health Care
GREAT POINT PARTNERS LLC reported holding 352,180 shares of NGNE (NEUROGENE INC COM) in its Q2 2026 13F filing — a position valued at US$11.1M, representing 2.33% of its reported portfolio and ranking #19 among its reported holdings. GREAT POINT PARTNERS LLC has disclosed NGNE holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How GREAT POINT PARTNERS LLC's NGNE position evolved
GREAT POINT PARTNERS LLC first disclosed a stake in NGNE in Q4 2023 at 994,229 shares (US$19.3M). The position peaked in Q1 2024 at 1,004,291 shares, worth US$51.1M. Across 11 filings, GREAT POINT PARTNERS LLC increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 352,180 shares valued at US$11.1M — a reduction of -147,820 shares quarter over quarter.. Notable position changes include a 56% trim in Q4 2024 (shares fell 49% over the following quarter), a 43% increase in Q1 2026 (shares rose 56% over the following quarter), a 30% trim in Q2 2026 (shares fell 12% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 994.23K | $19.27M | New |
| Q1 2024 | 1.00M | $51.12M | Add |
| Q2 2024 | 1.00M | $36.55M | Hold |
| Q3 2024 | 1.00M | $42.14M | Hold |
| Q4 2024 | 442.76K | $10.12M | Reduce |
| Q1 2025 | 470.96K | $5.51M | Add |
| Q2 2025 | 485.86K | $7.26M | Add |
| Q3 2025 | 446.81K | $7.74M | Reduce |
| Q4 2025 | 350.00K | $7.21M | Reduce |
| Q1 2026 | 500.00K | $10.08M | Add |
| Q2 2026 | 352.18K | $11.08M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NGNE and 13F data
NGNE (NEUROGENE INC COM) is a Health Care company. 37 other funds we track also report a position in NGNE — the largest reported positions include Samsara BioCapital, LLC (US$54.0M), Casdin Capital (US$48.6M), Redmile Group, LLC (US$44.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NGNE
- Samsara BioCapital, LLC 1.72M sh · $54.00M · Q2 2026
- Casdin Capital 1.55M sh · $48.60M · Q2 2026
- Redmile Group, LLC 1.41M sh · $44.41M · Q2 2026
- RTW INVESTMENTS, LP 1.36M sh · $42.85M · Q2 2026
- EcoR1 Capital, LLC 1.27M sh · $39.98M · Q2 2026
- BAKER BROS. ADVISORS LP 991.69K sh · $31.19M · Q2 2026
- Trails Edge Capital Partners, LP 714.88K sh · $22.48M · Q2 2026
- DAFNA Capital Management LLC 89.03K sh · $2.80M · Q2 2026
More on GREAT POINT PARTNERS LLC
FAQ
How long has GREAT POINT PARTNERS LLC held NGNE?
GREAT POINT PARTNERS LLC has disclosed NGNE holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
What is GREAT POINT PARTNERS LLC's current position in NGNE?
As of Q2 2026, GREAT POINT PARTNERS LLC holds 352.18K shares of NGNE (NEUROGENE INC COM), valued at $11.08M, representing 2.33% of its reported portfolio and ranking #19.
Has GREAT POINT PARTNERS LLC been buying or selling NGNE?
In the latest 13F filing (Q2 2026), GREAT POINT PARTNERS LLC reduced its position in NGNE. The position peaked in Q1 2024 at 1.00M shares.
Which other funds hold NGNE?
Other major institutional holders of NGNE include Samsara BioCapital, LLC, Casdin Capital, Redmile Group, LLC, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.